Extract
Interstitial lung diseases (ILD) are a heterogeneous entity of diffuse parenchymal lung diseases, characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of two to three years [2–4]. Pirfenidone (Esbriet®) and nintedanib (Ofev®) were approved as IPF treatment showing a stabilisation of the disease [5, 6] and are the recommended treatments by international guidelines [1]. Nintedanib was shown to increase the risk for bleeding events in IPF patients during therapy [7], and the European Medicines Agency (EMA) recommended discontinuation of nintedanib before major surgery without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11].
Abstract
New antifibrotic therapies do not impair the clinical course and survival in patients with ILD who underwent DLuTX
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Ius has nothing to disclose.
Conflict of interest: Dr. Tudorache has nothing to disclose.
Conflict of interest: Ms Boehm has nothing to disclose.
Conflict of interest: Dr. Jaksch has nothing to disclose.
Conflict of interest: Dr. Klepetko has nothing to disclose.
Conflict of interest: Dr. Lambers reports other from Boehringer Ingelheim, other from Roche, outside the submitted work.
Conflict of interest: Dr. Lee has nothing to disclose.
Conflict of interest: Dr. Ristl has nothing to disclose.
Conflict of interest: Dr. Welte reports grants from Boehringer and Roche during the conduct of the study; personal fees from Boehringer and from Roche outside the submitted work; .
Conflict of interest: Jens Gottlieb
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
